Cargando…

Five-Year Survival Among Stage IIIA Lung Cancer Patients Receiving Two Different Treatment Modalities

BACKGROUND: Five-year survival rates among stage IIIA lung cancer patients range between 2% and 15%, and there is currently no consensus regarding optimal treatment approaches for these patients. The current investigation evaluated survival outcomes among stage IIIA lung cancer patients receiving 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bilfinger, Thomas, Keresztes, Roger, Albano, Denise, Nemesure, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2016
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017688/ https://www.ncbi.nlm.nih.gov/pubmed/27442604 http://dx.doi.org/10.12659/MSM.898675

Ejemplares similares

1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT
por: Albano, Denise, et al.
Publicado: (2018)

Clinical Implications of “Atypia” on Biopsy: Possible Precursor to Lung Cancer?
por: Albano, Denise, et al.
Publicado: (2021)

Morphologic Severity of Atypia Is Predictive of Lung Cancer Diagnosis
por: Santore, Lee Ann, et al.
Publicado: (2023)

An Assessment of Distress Levels of Patients Undergoing Lung Cancer Treatment and Surveillance During the COVID-19 Pandemic
por: Albano, Denise, et al.
Publicado: (2021)

Risk Stratification of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Chemo-Radiotherapy: An Institutional Analysis
por: Sher, Amna, et al.
Publicado: (2020)

Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer
por: Hoff, John, et al.
Publicado: (2014)

Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non–Small Cell Lung Cancer Patients Receiving Definitive Chemoradiotherapy
por: Guberina, Maja, et al.
Publicado: (2021)

Outcome of Endometrial Cancer Stage IIIA with Adnexa or Serosal Involvement Only
por: Jobsen, Jan J., et al.
Publicado: (2011)

Combined modality therapy in Stage IIIA non–small cell lung cancer: clarity or confusion despite the highest level of evidence?
por: Jeremic, Branislav, et al.
Publicado: (2017)

Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study
por: Wisnivesky, Juan P, et al.
Publicado: (2011)

Randomised study of adjuvant chemotherapy for completely resected p-stage I–IIIA non-small cell lung cancer
por: Nakagawa, K, et al.
Publicado: (2006)

Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression
por: Chen, Zhiwei, et al.
Publicado: (2017)

Prognostic value of number of negative lymph node in patients with stage II and IIIa non-small cell lung cancer
por: Wang, Shengguang, et al.
Publicado: (2017)

The Prognosis According to Patterns of Mediastinal Lymph Node Metastasis in Pathologic Stage IIIA/N2 Non-Small Cell Lung Cancer
por: Kim, Do Wan, et al.
Publicado: (2014)

Survival Contradiction Between Stage IIA and Stage IIIA Rectal Cancer: A Retrospective Study
por: Mo, Shaobo, et al.
Publicado: (2018)

Re-Evaluation of the Survival Paradox Between Stage IIB/IIC and Stage IIIA Colon Cancer
por: Li, Hongbo, et al.
Publicado: (2020)

Surgical Management of Stage IIIA Non-Small Cell Lung Cancer
por: Van Schil, Paul E., et al.
Publicado: (2017)

Comprehensive Characterization of Stage IIIA Non-Small Cell Lung Carcinoma
por: Singh, Neetu, et al.
Publicado: (2020)

Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer
por: Wang, Bing-Yen, et al.
Publicado: (2016)

Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities
por: Deng, Wei, et al.
Publicado: (2020)

Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC
por: Agrawal, Vishesh, et al.
Publicado: (2017)

The prognosis of clinical stage IIIa non‐small cell lung cancer in Taiwan
por: Cheng, Ya‐Fu, et al.
Publicado: (2023)

Effects of Neoadjuvant Radiotherapy on Survival in Patients with Stage IIIA-N2 Non-Small-Cell Lung Cancer Following Pneumonectomy
por: Qu, Chenghao, et al.
Publicado: (2022)

Preoperative Concurrent Radiochemotherapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer
por: Kang, Min Kyu, et al.
Publicado: (2006)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis
por: Xu, Ya-Ping, et al.
Publicado: (2015)

Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status
por: Isaka, Tetsuya, et al.
Publicado: (2022)

Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study
por: Chen, Zhiwei, et al.
Publicado: (2019)

Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
por: Dan, Aravot, et al.
Publicado: (2019)

Revaluating the survival effects of International Federation of Gynecology and Obstetrics 1988 stage IIIA criteria for endometrial cancer
por: Türkmen, Osman, et al.
Publicado: (2017)

Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
por: Betticher, D C, et al.
Publicado: (2006)

Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer
por: Palka, Magda, et al.
Publicado: (2017)

Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer
por: Montemuiño Muñiz, Sara, et al.
Publicado: (2021)

Bone metastasis after stage IIIA non-small cell lung cancer: risks and prognosis
por: de Bessa, Camila Martins, et al.
Publicado: (2022)

Outcomes of Pulmonary Resection and Mediastinal Node Dissection by Video-Assisted Thoracoscopic Surgery Following Neoadjuvant Chemoradiation Therapy for Stage IIIA N2 Non-Small Cell Lung Cancer
por: Jeon, Yeong Jeong, et al.
Publicado: (2018)

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
por: Herbst, Roy S., et al.
Publicado: (2023)

Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma
por: Yoon, Mee Sun, et al.
Publicado: (2016)

Racial Disparity and Social Determinants in Receiving Timely Surgery Among Stage I–IIIA Non-small Cell Lung Cancer Patients in a U.S. Southern State
por: Neroda, Paige, et al.
Publicado: (2021)

Construction and Validation of Nomograms for Predicting Overall Survival and Cancer-Specific Survival in Nonmetastatic Inflammatory Breast Cancer Patients Receiving Tri-Modality Therapy: A Population-Based Study
por: Huang, Qin, et al.
Publicado: (2019)

Correction to: Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
por: Aravot, Dan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sj3i4h21v9umh87mlh3028nqi2